-

Maravai LifeSciences Announces November 2025 Investor Conference Schedule

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November.

On November 12, 2025, at 10:00 a.m. EST, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY.

On November 19, 2025, at 10:00 a.m. GMT, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London, England.

A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, IR Calendar. An archived version of the webcast will also be available on the Maravai website after the event is completed.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Contacts

Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com

Maravai LifeSciences, Inc.

NASDAQ:MRVI

Release Versions

Contacts

Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com

More News From Maravai LifeSciences, Inc.

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs...

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th...

Maravai LifeSciences Reports First Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc...
Back to Newsroom